Aprea Therapeutics, Inc. SEC filings APRE
Aprea Therapeutics, Inc. has 446 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B7 | Filing | May 15, 2026 | — |
| 424B3 | Prospectus | Apr 29, 2026 | — |
| S-3 | Shelf registration | Apr 22, 2026 | — |
| 424B3 | Prospectus | Mar 19, 2026 | — |
| S-3/A | Filing | Mar 17, 2026 | — |
| S-8 | Employee stock plan registration | Mar 16, 2026 | — |
| S-3 | Shelf registration | Feb 20, 2026 | — |
| 424B3 | Prospectus | Dec 30, 2025 | — |
| S-3 | Shelf registration | Dec 19, 2025 | — |
| S-8 | Employee stock plan registration | Dec 8, 2025 | — |
| 424B5 | Prospectus supplement | Nov 8, 2024 | — |
| S-8 | Employee stock plan registration | Aug 21, 2024 | — |
| 424B3 | Prospectus | Apr 30, 2024 | — |
| S-3 | Shelf registration | Apr 3, 2024 | — |
| 424B3 | Prospectus | Feb 9, 2024 | — |
| 424B3 | Prospectus | Feb 5, 2024 | — |
| S-3 | Shelf registration | Jan 26, 2024 | — |
| S-8 | Employee stock plan registration | Nov 9, 2023 | — |
| 424B5 | Prospectus supplement | Feb 24, 2023 | — |
| 424B5 | Prospectus supplement | Feb 22, 2023 | — |
| S-8 | Employee stock plan registration | Dec 15, 2022 | — |
| 424B5 | Prospectus supplement | Sep 2, 2022 | — |
| S-8 | Employee stock plan registration | Jun 3, 2022 | — |
| S-8 | Employee stock plan registration | Nov 9, 2021 | — |
| S-3/A | Form s-3/a | Nov 24, 2020 | — |
| S-8 | Employee stock plan registration | Nov 12, 2020 | — |
| S-3 | Shelf registration | Nov 12, 2020 | — |
| S-8 | Employee stock plan registration | Nov 18, 2019 | — |
| 424B4 | Prospectus | Oct 4, 2019 | — |
| FWP | Free writing prospectus | Oct 3, 2019 | — |
| S-1MEF | Filing | Oct 2, 2019 | — |
| S-1/A | Amended registration statement | Oct 2, 2019 | — |
| S-1/A | Amended registration statement | Sep 27, 2019 | — |
| S-1/A | Amended registration statement | Sep 25, 2019 | — |
| S-1/A | Amended registration statement | Sep 23, 2019 | — |
| S-1 | Registration statement | Sep 6, 2019 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APRE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Doylestown, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1781983
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.